Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
Chronic Hepatitis C, People Who Inject Drugs
About this trial
This is an interventional treatment trial for Chronic Hepatitis C
Eligibility Criteria
Inclusion Criteria: Chronic HCV infection and PWID arm: use of intravenous drug use at least once in preceding six months. In Non-PWID arm: no use of intravenous drug use at least once in preceding six months. Exclusion Criteria: Co-infection with chronic hepatitis B; Decompensated cirrhosis current or by history; inability to sign informed consent; unwilling to take therapy or unable to obtain therapy
Sites / Locations
- Wellstar Atlanta Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
PWID (people who inject drugs)
Non-PWID
velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic) in subjects who had used intravenous drugs at least once in preceding six months.
velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic) in subjects who had NOT used intravenous drugs at least once in preceding six months, but were treated concurrently in the same hepatology referral clinics.